Recursion Pharmaceuticals vs Ankr
Side-by-side comparison of AI visibility scores, market position, and capabilities
Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.
About
Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.
Decentralized Web3 infrastructure with RPC node access across 30+ blockchains; globally distributed nodes reduce latency; premium dedicated nodes for apps needing guaranteed throughput.
About
Ankr is a Web3 infrastructure platform offering remote procedure call node access to more than 30 blockchain networks through a globally distributed network of nodes run by independent operators. Unlike centralized providers that operate their own data centers exclusively, Ankr's decentralized architecture routes requests across geographically distributed nodes, improving latency for users in regions underserved by US- or EU-centric infrastructure. Its public free-tier RPC endpoints — available for Ethereum, BNB Chain, Polygon, Avalanche, Fantom, and dozens of others — have made Ankr one of the most widely used infrastructure providers in the multi-chain developer ecosystem.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.